| Gene symbol | ANPEP | Synonyms | AP-M, AP-N, APN, CD13, GP150, LAP1, P150, PEPN, hAPN | Type of gene | protein-coding |
| Chromosome | 15 | Map location | 15q26.1 | dbXrefs | |
| Description | alanyl aminopeptidase, membrane | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| Gene symbol | CD70 | Synonyms | CD27-L, CD27L, CD27LG, LPFS3, TNFSF7, TNLG8A | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19p13.3 | dbXrefs | |
| Description | CD70 molecule | ||||
| Gene symbol | CD79B | Synonyms | AGM6, B29, IGB, Igbeta | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q23.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD79b molecule | ||||
| Gene symbol | FOLH1 | Synonyms | FGCP, FOLH, GCP2, GCPII, NAALAD1, PSM, PSMA, mGCP | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11p11.12 | dbXrefs | |
| Description | folate hydrolase 1 | ||||
| GTO ID | GTC2378 |
| Trial ID | NCT04429438 |
| Disease | B-Cell Lymphoma |
| Altered gene | CD19|CD20|CD22|CD70|CD13|CD79b|GD2|PSMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | 4SCAR-T cells |
| Generation | 4th |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Multi-CAR-T Cells Targeting B Cell Lymphomas |
| Year | 2020 |
| Country | China |
| Company sponsor | Shenzhen Geno-Immune Medical Institute |
| Other ID(s) | GIMI-IRB-20006 |
| Cohort 1 | |||||||
|
|||||||